MET and hepatocellular carcinoma: As cabozantinib, a multi-target kinase inhibitor targeting MET and VEGFR2, has shown positive clinical trial results in improving survival in advanced HCC [24], combining MET inhibitors with immune checkpoint inhibitors to improve therapeutic efficacy are certainly the future directions.